Skip to content

HIV still busy when ''undetectable''

Salvage therapy: new protease inhibitors promising

Hepatitis B and C increase risk of liver toxicity after starting HAART

Nevirapine use in PEP: concerns over rash

Australian HIV vaccine shows promise

Another drug bites the dust: Glaxo-Wellcome drop NNRTI

Disappointing amprenavir results: only 30% undetectable at 48 weeks

Male breast enlargement seen with all drug classes

Therapeutic drug monitoring: quality control still needed, international study shows

UK trial finds no diffference in failure rates of thicker versus standard condoms for gay men

Brazil pulls plug on HIV drugs in budget crisis

Hep C drug may increase nucleoside analogue toxicity

HIV rates not falling in gay men; drug resistance rising in new cases

Oral sex risk – Australians find no risk

Frankfurt resistance meeting highlights

Brussels and Barcelona patients join Berlin patient in lack of viral rebound after treatment break

High viral load main risk factor in mother-to-baby transmission

'Bareback' sex ten times more risky for passive partner of HIV+ man than active partner